Company Overview and News

38
Lithium Investment: Balancing Battery Demand Against Innovative Production And Supply

2018-05-29 seekingalpha
So much so, that many users are jumping in with investment dollars to stimulate and foster growth.
PLS PCRFY PILBF ALB LTUM FTI.WI TYHOF TOP FMC LACDF NMKEF ENRT AVLIF NMX 8015 RHHNF OROCF MLNLF LAC

51
Lithium Investing: Asian Supply Chain Races To Secure Lithium

2018-05-04 seekingalpha
Strong lithium chemical pricing has pushed battery and material manufacturers to enter agreements with lithium explorers and producers.
TM TYHOF TYT LACDF TOYOF JODRF AVLIF 7203 TSLA 8015 OROCF MLNLF LAC

45
33
Lithium Prices Remain Strong In Q1 2018

2018-04-25 seekingalpha
After a multi-year increase in lithium prices, they continue to remain strong in Q1 2018; an overview of what has transpired and driving firm prices.
ALB AVLIF TYHOF LACDF 8015 OROCF MLNLF LAC

42
Lithium Investing: Capital Continues To Flow Into Lithium Assets As Demand Rises

2018-04-16 seekingalpha
Battery production continues to climb as automakers bring new options to market; new energy vehicle sales figures continue to rise.
PILBF SSNLF ALB TYHOF LACDF 2333 NMKEF GALXF GCPEY ALTAF NMX OROCF EGT MLNLF EGTYF LAC PLS PCRFY GCPEF GWLLY SSDIY GXY 8015 PKXFF AJM STGYF

41
Why Lithium Is About To Replace Oil

2018-04-08 seekingalpha
What we are witnessing now is nothing less that the transition from a carbon- to a lithium-based economy.
ALB FMC SQM MLNLF

33
Lithium Investing: Focus On Advanced Explorers And Early Stage Production Companies

2018-04-03 seekingalpha
Rising demand for electric vehicles and energy storage systems, lithium is now in short supply; Asia continues to ramp-up battery production to meet new demand.
GCPEF ALB TYHOF LACDF NMKEF AVLIF GCPEY NMX 8015 OROCF MLNLF LAC

48
Lithium Junior Miner News For The Month Of March 2018

2018-03-28 seekingalpha
Lithium spot and contract price news - Lithium spot prices moved sideways, whilst 2018 global LCE contract prices are up about 20%.
LIT SAV LAXXF LIACF PFFOF WML POR ABEPF SQM MLNLF VLKAY AVLNF AIS.H KDR SYA STLHF WMLLF LNRDY HMGLF PEMIF ABE NGZ LMMFF GXY LRS PLU MNIKF HNR AMLM AVL ALB DMNXF NMKEF LKE MGXMF PLUUF DJIFF NMX PSC EMH CRECF ERPNF PLS MSB DJI SSDIY PDDTF NTTHF AVLIF ORE AVZ AJM

154
Resource Sector Digest: The Market Is Right About Eldorado Gold

2018-03-27 seekingalpha
In case you missed out on previous editions of this newsletter, simply click here, here or here to catch up.
CNR CAT DGDCF THO BYAGF BTG ACA AEM FQM MLNLF ABX TAHO RPM ALO OKSWF ABGLF RPMGD KLDX CDEUW RPMGF RVRCF CDE AGD RGLD AUG ABGLY NCMGY AGDXF OSKGF BYN DYG GTGDF RGL NCMGF NCM CG VITFF CAGDF KDX OR FQVLF GG HL.PRB EGO GGTCF ABX VIT CBLLF ELD ITH HL IDMMF AUG IDM

4
A Rising Tide Of Chinese Investment Into The Canadian Lithium Sector

2018-03-15 seekingalpha
Canadian lithium executives have done an outstanding job at attracting hundreds of millions in investments from strategic Chinese plays.
JODRF NTTHF AVLIF NMX TYHOF LACDF 8015 OROCF MLNLF NMKEF

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...